The C-suite executives allegedly improperly recognized revenue from distributors with which MiMedx had secret side arrangements.
The deal expands Gilead's investment in the European biotech as it seeks to add assets to its drug portfolio.
The opioid seller's auditor expressed "substantial doubt" about its ability to continue as a going concern.
The startup's IPO would raise capital for "a new category of transformative medicines based on messenger RNA."
The $2.4 billion purchase of 44% of Foundation Medicine raises Roche's bet on the development of personalized cancer treatments and care.
The biotech firm's stock falls 23% but its CEO says, "It is important that investors understand that our business performance remains strong."
Should publicly held, early stage biotechs issue more shares or partner with Big Pharma?
The acquisition of Bioverativ boosts Sanofi's presence in the fast-growing, $10 billion market for hemophilia treatments.
You don't necessarily need experience in the firm's specific niche. In many cases, other aspects of your background are more important.
Former CFOs Philip Jacoby and Gregory Law are among those charged with inflating the biotech firm's revenue to meet the CEO's aggressive targets.
The drugmaker is restructuring as it tries to rebuild its drug pipeline amid investigations of its sales practices.
If Baruch Lev is right, the old models don’t work anymore.
